Trials / Completed
CompletedNCT04389268
P300 in Early Cognitive Impairment in Hepatitis C Virus
Predictive Value of P300 Event-related Potential Component in Early Cognitive Impairment in Patients With Uncomplicated Newly Diagnosed Hepatitis C Virus
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Mansoura University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
Approximately 50% of patients with hepatitis C have complaints of fatigue and cognitive deficits even before the development of significant hepatic impairment.
Detailed description
Assessing the influence of HCV infection on the development of cognitive changes involves many challenges. The frequent presence of confounding factors such as illicit drug use, depression, and cirrhosis has the potential to produce cognitive impairment and therefore obscuring the role of HCV infection as a major actor in the development of cognitive impairment. The presence of brain dysfunction in patients with liver cirrhosis is well known. Zeegen et al. described in 1970, through the use of neuropsychological tests, the occurrence of cognitive changes involving mainly psychomotor speed, attention, and executive function in cirrhotics who did not have clinical criteria for hepatic encephalopathy. This condition is currently called minimal hepatic encephalopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Visual Event-Related Potentials | Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995). |
Timeline
- Start date
- 2018-02-01
- Primary completion
- 2019-01-01
- Completion
- 2019-02-01
- First posted
- 2020-05-15
- Last updated
- 2020-05-15
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04389268. Inclusion in this directory is not an endorsement.